Upstate Active Clinical Trials

Study Title:

Exploration of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity Following Various Administration Schedules with CYD Tetravalent Dengue Vaccine, a Phase II, Randomized, Open-Label, Single Center Trial in Adults Aged 18-45 Years in the US.

What is the purpose of the study?

To evaluate the safety and immunogenicity of CYD Dengue Vaccine for the military/traveler indication. Dengue Fever is a disease that affects many parts of the developing world as well as parts of the United States.

Upstate Institutional Review Board (IRB) Number:

458738

Study Phase:

II

Patient Age Group:

Adults

Principal Investigator:

Mark E Polhemus, MD

What is involved if I participate?

  • How long is the study?
    18 months
  • Is transportation provided or reimbursed?
    Yes
  • Is parking provided or reimbursed?
    Yes
  • What tests and procedures are involved?
    Blood draws Other: Vital sign assessments, physical exam and medical history

Where will the study take place?

505 Irving Avenue, Syracuse, NY 13210 (Institute for Human Performance)

Other Information:

Nov 2013 to Oct 2015

ClinicalTrials.Gov ID:

NCT01943825

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Gina D Bertolo
Phone: 315-464-7693
Email: trials@upstate.edu

Return to Previous Page || Search Again